Trevi Therapeutics shares are trading higher after BMO Capital initiated its coverage on the stock with an Outperform rating and announced a price target of $36.benzinga_article·Jul 21 at 09:32 AMTRVI-1.84%
This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga_article·Jul 21 at 06:58 AMTRVI-1.84%ELDN-2.65%
This Urban Outfitters Analyst Turns Bullish; Here Are Top 5 Upgrades For Mondaybenzinga_article·Jul 20 at 06:28 AMURBN+0.27%USB-A-0.12%
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga_article·Jul 14 at 07:05 AMBJDX-12.14%PLRZ+3.91%
5 Biotech Stocks That Delivered Triple-Digit Gains - SYRE Up 400%, BFLY Up 300% & Morerttnews·Jun 20 at 05:19 AMSYRE-2.09%TRVI-1.84%
Trevi Therapeutics management attends BIO International Convention in June and July eventsPUBT·Jun 17 at 06:30 AMTRVI-1.84%
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters.nasdaq·Jun 3 at 09:10 AMTRVI-1.84%
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030Market Beat·May 9 at 04:05 AMTRVI-1.84%IHE-0.44%
Research Analysts Set Expectations for TRVI FY2030 EarningsMarket Beat·May 7 at 07:35 AMTRVI-1.84%VHT-0.61%
Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI)Tip Ranks·May 6 at 06:46 AMTRVI-1.84%PBE-0.66%
Analyst Reiterates Buy on Trevi Therapeutics, Slightly Lowers Price Target to $23 Amid Advancing Haduvio PipelineTip Ranks·May 5 at 11:55 PMTRVI-1.84%
Trevi Therapeutics Q1 2026 Earnings Call Transcriptbenzinga_article·May 5 at 04:20 PMTRVI-1.84%ARKG-0.85%
